CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis
CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis
复制标题
DOI：
10.1038/sj.leu.2402174
复制
发表时间：
2001-08-01
期刊：
影响因子：
11.4
通讯作者：
Lauria, F
中科院分区：
文献类型：
--
作者：
Raspadori, D;Damiani, D;Lauria, F
CD56抗原是一种200-220 kDa的细胞表面糖蛋白，被鉴定为神经粘附分子（NCAM）的异构体，已发现在包括急性髓性白血病（AML）在内的几种淋巴-造血肿瘤中经常表达。事实上，在这些后一种疾病中，有报道称，在t(8;21) （q22;q22）和M3亚型AML患者的原细胞上存在CD56抗原，确定了一个预后更不利的患者亚群。在此基础上，我们评估了152例新诊断的AML患者CD56表面表达，结果与形态学、免疫表型、细胞遗传学模式和临床结果相关。在152例患者中，有37例（24%）检测到CD56抗原，其中M2和M5细胞型患者尤为明显。此外，CD56表达与P-糖蛋白（PGP）高表达（P = 0.007）、不利的细胞遗传学异常（P = 0.008）、实现完全缓解（CR）的可能性降低（36%对68%）（P = 0.035）以及生存期缩短（6个月对12个月）（P = 0.032）显著相关。总之，AML细胞上的CD56抗原表达是一个重要的不良预后因素，因此应定期调查其存在，以便在诊断时更好地评估AML患者的预后。
CD56 antigen, a 200-220 kDa cell surface glycoprotein, identified as an isoform of the neural adhesion molecules (NCAM), has been found frequently expressed in several lympho-hematopoietic neoplasms including acute myeloid leukemias (AML). In fact, in these latter diseases it has been reported that the presence of CD56 antigen on the blasts of AML patients with t(8;21) (q22;q22), and in those with M3 subtype, identifies a subgroup of patients with a more unfavorable prognosis. On the basis of these findings, we evaluated in 152 newly diagnosed AML patients CD56 surface expression, and results were correlated with morphology, immunophenotype, cytogenetic pattern and clinical outcome. CD56 antigen was recorded in 37 out of 152 cases (24%) and particularly in those with M2 and M5 cytotypes. Moreover, CD56 expression was significantly associated with P-glycoprotein (PGP) hyperexpression (P = 0.007), unfavorable cytogenetic abnormalities (P = 0.008) and with a reduced probability of achieving complete remission (CR) (36% vs 68%) (P = 0.035) as well as with a shorter survival (6 vs 12 months) (P = 0.032). In conclusion, CD56 antigenic expression on AML cells represents an important adverse prognostic factor and therefore its presence should be regularly investigated for a better prognostic assessment of AML patients at diagnosis.